Melanoma in a patient with previously unrecognized Birt-Hogg-Dubé syndrome

Somaira Nowsheen, a Jennifer L. Hand, MD, b,c,d Lawrence E. Gibson, MD, b,c and Rokea A. el-Azhary, MD, PhD
Rochester, Minnesota

Key words: Birt-Hogg-Dubé syndrome; cancer; dermatology; fibroadenoma; melanoma; moles; papules.

INTRODUCTION

Birt-Hogg-Dubé syndrome (BHDS) is an uncommon genetic disorder affecting the skin, lungs, and kidneys. It is characterized by numerous benign skin tumors (fibrofolliculomas, trichodiscomas, and acrochordons), especially on the face, neck, and chest.1 Although BHDS has a well-known link with malignancy, especially renal cancer, it is infrequently considered in dermatology patients with atypical nevi and melanoma.2 However, increased melanoma risk, including choroidal melanoma, is associated with BHDS.3-9 Here, we report a patient with multiple primary cutaneous melanomas and atypical nevi that triggered evaluation for an underlying genetic cause. We bring this underreported clinical co-occurrence to the attention of dermatologists.

CASE REPORT

A 50-year-old woman with Fitzpatrick type 1-2 skin and a history of melanoma and atypical nevi presented for her recommended biannual dermatologic evaluation. Despite adherence to sun protection measures, prior dermatology examinations over 18 years had shown 15 biopsy-proven atypical nevi. Three were severely atypical, and 12 were moderately atypical. Just 4 months earlier, malignant melanoma, superficial spreading type (Breslow thickness of 0.7 mm and immunoreactive for melan A), was diagnosed from the anterior portion of her right forearm. Environmental risk factors included a limited, remote history of tanning bed use over 1 year and sunburns but no outdoor work or immunosuppression. She denied any history of lung or renal disease. On examination, tan-brown nevi of various sizes in a widely scattered distribution and a slightly darker suspicious site on the right back-lateral aspect of the lower leg were noted. Biopsy showed superficial spreading melanoma, Breslow thickness of 0.28 mm, and positive melan A reactivity (Fig 1). This unexpected history of 2 new melanomas over a short period prompted more careful review. Genetics consultation with detailed family history showed paternal renal cysts requiring surgical removal and a brother and son each having dysplastic nevi and singular malignant melanoma at an unknown age and age 21 years, respectively. On skin examination, numerous firm, whitish, dome-shaped papules were noted on her face, chest, and back. Three subtle lesions were biopsied, and 1 histologically confirmed fibrofolliculoma was noted, which meets the criterion for dermatologic diagnosis of this syndrome (Fig 2 and Table I).1 After pretest counseling with a genetics specialist, the patient was offered testing for an FLCN mutation. She declined because of cost and the potential for insurance discrimination.

DISCUSSION

BHDS is a rare autosomal dominant disorder affecting not only the skin but also the respiratory and renal systems. The clinical presentation varies

JAAD Case Reports 2019;5:947-52.
2352-5126 © 2019 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jdcr.2019.08.018
greatly among affected individuals, even in the same family. Spontaneous pneumothorax due to lung cysts may be one of the earliest manifestations, and up to one third of individuals with BHDS have a lifetime likelihood of developing renal tumors. More than 90% of patients present with benign cutaneous manifestations, which are generally noted in a person’s 20s or 30s, and these progressively increase in number and size over time. Despite progression, skin features are rarely cosmetically disfiguring and do not come to medical attention. Multiple melanomas and atypical nevi, however, are more likely to draw the attention of a dermatologist, especially when more than 1 melanoma is present in the same patient.

In general, skin cancer risk is considered to be multifactorial, that is, due to a combination of factors...
| Study        | Study description                                                                 | Mutational analysis | Dermatologic assessment | Pulmonary involvement | Renal involvement | Others                                      |
|-------------|----------------------------------------------------------------------------------|---------------------|-------------------------|-----------------------|-------------------|--------------------------------------------|
| Sattler et al\textsuperscript{8} | Multinational European study assessing the prevalence of dysplastic nevi and cutaneous melanoma in a cohort of BHDS families | • FLCN mutation present in 32 of 33 families  
• No mutations in genes known to predispose individuals to cutaneous melanoma identified | • 10% diagnosed with cutaneous melanoma  
— Age, 52-90 years  
— >60% female  
— 62.5% invasive stage I-IV  
• 49% diagnosed with dysplastic nevi | N/A | N/A | N/A |
| Jaster and Wachsmann\textsuperscript{11} | Case report of a 64-year-old man with BHDS receiving immunosuppression therapy for renal transplantation | N/A | Malignant melanoma | Malignant mesothelioma, epithelial subtype | Polycystic kidney disease | N/A |
| Mota-Burgos et al\textsuperscript{4} | Case report of a 54-year-old man with BHDS | FLCN mutation present | None | None | Several colorectal tubulovillous adenomas |
| Study                          | Study description                          | Mutational analysis | Dermatologic assessment | Pulmonary involvement | Renal involvement | Others                          |
|-------------------------------|--------------------------------------------|---------------------|--------------------------|-----------------------|-------------------|---------------------------------|
| Kasi and Dearmond⁵            | Case report of a 70-year-old man with BHDS | N/A                 | • Multiple acrochordons  | Multiple pulmonary cysts | Clear cell renal cell carcinoma and bilateral renal cysts | Colorectal tubulovillous adenoma |
| Cocciolone et al⁹             | Case report of a 58-year-old man with BHDS | FLCN mutation present | • 2 desmoplastic melanomas on right cheek and left shoulder | History of spontaneous pneumothorax | None               | Salivary gland oncocytoma       |
| Welsch et al⁵                 | Case report of a 52-year-old man with BHDS | N/A                 | • Cutaneous lesions appeared progressively in his late 30s | Solitary bullae in right lung and history of pneumothorax | Chromophobe-type renal cell carcinoma | Multinodular goiter             |
| Toro et al¹²                  | Case series assessing renal findings in 28 BHDS patients | FLCN mutation present in 1 of 2 patients | • Melanocytic nevi in a 61-year-old woman | N/A                   | Renal oncocytoma and bilateral solid lesions | N/A                            |
such as genetics, environment, and random chance. This patient endorsed some environmental risk factors for melanoma but not others. Her striking history of multiple melanomas despite sun protection suggested a genetic cause and prompted more careful review. Genetic consultation included closer review of family history and physical examination for signs of a genetic cancer syndrome to improve the accuracy of genetic testing or make a diagnosis. This review found multiple, previously unrecognized facial papules suspicious for BHDS.

A literature review for association of BHDS and melanoma showed a case series reporting 8 patients with cutaneous melanoma diagnoses in a cohort of 83 individuals with BHDS. Similar to our case, 1 patient had multiple primary diagnoses of melanoma. Interestingly, the rate of melanoma increased from 2.1% in the general population to 10% for patients with BHDS. Table II summarizes all reports of cutaneous melanoma in patients with BHDS to date. Further studies are warranted to determine the lifetime risk of melanoma in patients with BHDS and how environmental factors and skin type influence this risk.

BHDS is caused by mutations in the tumor suppressor folliculin (FLCN), which is expressed in and is important for the development of skin, lungs, and kidneys. Loss of FLCN constitutively activates adenosine monophosphate–activated protein kinase (AMPK), a key enzyme that regulates energy metabolism and melanogenesis. Constitutive activation of AMPK leads to autophagy and resistance to many stressors that would normally kill atypical cells. This eventually leads to cellular transformation and, possibly, tumor formation. Autophagy has been strongly linked to the formation of melanoma. This is likely the same process responsible for melanoma in patients with BHDS, but further work is warranted in this area.

Because of the subtle presentation of the BHDS lesions, we recommend obtaining a thorough family history in patients with multiple primary melanomas and a careful examination for subtle facial and upper body follicular papules due to the increased possibility of BHDS. In addition, the reverse applies as well. Patients with suspected BHDS should be examined for abnormal or dysplastic moles and potentially melanoma.

REFERENCES

1. Toro JR. Birt-Hogg-Dubé syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews. Seattle, WA: University of Washington, Seattle; 1993.
2. Schmidt LS, Linehan WM. FLCN: the causative gene for Birt-Hogg-Dubé syndrome. Gene. 2016;640:28-42.
3. Welsch MJ, Krunic A, Medenica MM. Birt-Hogg-Dubé syndrome. *Int J Dermatol*. 2005;44:668-673.
4. Mota-Burgos A, Acosta EH, Marquez FV, Mendiola M, Herrera-Ceballos E. Birt-Hogg-Dubé syndrome in a patient with melanoma and a novel mutation in the FCLN gene. *Int J Dermatol*. 2013;52:323-326.
5. Kasi PM, Dearmond DT. Birt-Hogg-Dubé syndrome: answering questions raised by a case report published in 1962. *Case Rep Oncol*. 2011;4:363-366.
6. Fontcuberta IC, Salomao DR, Quiram PA, Pulido JS. Choroidal melanoma and lid fibrofolliculomas in Birt-Hogg-Dubé syndrome. *Ophthalmic Genet*. 2011;32:143-146.
7. Marous CL, Marous MR, Welch RJ, Shields JA, Shields CL. Choroidal melanoma, sector melanocytosis, and retinal pigment epithelial microdetachments in Birt-Hogg-Dubé syndrome. *Retin Cases Brief Rep*. 2017;13(3):202-206.
8. Sattler EC, Ertl-Wagner B, Pellegrini C, et al. Cutaneous melanoma in Birt-Hogg-Dubé syndrome: part of the clinical spectrum? *Br J Dermatol* 2018;178:e132-e133.
9. Cacciolone RA, Crotty KA, Andrews L, Haass NK, Moloney FJ. Multiple desmoplastic melanomas in Birt-Hogg-Dubé syndrome and a proposed signaling link between folliculin, the mTOR pathway, and melanoma susceptibility. *Arch Dermatol*. 2010;146:1316-1318.
10. Steinlein OK, Ertl-Wagner B, Ruizcka T, Sattler EC. Birt-Hogg-Dubé syndrome: an underdiagnosed genetic tumor syndrome. *J Dtsch Dermatol Ges*. 2018;16:278-283.
11. Jaster A, Wachsmann J. Serendipitous discovery of peritoneal mesothelioma. *Proc (Bayl Univ Med Cent)*. 2016;29:185-187.
12. Toro JR, Glenn G, Duray P, et al. Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. *Arch Dermatol*. 1999;135:1195-1202.
13. Khoo SK, Giraud S, Kahnoski K, et al. Clinical and genetic studies of Birt-Hogg-Dubé syndrome. *J Med Genet*. 2002;39:906-912.
14. Warren MB, Torres-Cabala CA, Turner ML, et al. Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. *Mod Pathol*. 2004;17:998-1011.
15. Bang S, Won KH, Moon HR, et al. Novel regulation of melanogenesis by adiponectin via the AMPK/CRTC pathway. *Pigment Cell Melanoma Res*. 2017;30:553-557.
16. Yan M, Gingras MC, Dunlop EA, et al. The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation. *J Clin Invest*. 2014;124:2640-2650.
17. Possik E, Jalali Z, Nouët Y, et al. Folliculin regulates AMPK-dependent autophagy and metabolic stress survival. *PLOS Genet*. 2014;10:e1004273.
18. Pérez L, Sinn AL, Sandusky GE, Pollok KE, Blum JS. Melanoma LAMP-2C modulates tumor growth and autophagy. *Front Cell Dev Biol*. 2018;6:101.
19. Ferrarelli LK. Autophagy-independent p62 in metastatic melanoma. *Sci Signal*. 2019;12:eaw8024.
20. Xie X, White EP, Mehrert JM. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. *PloS One*. 2013;8:e55096.
21. Alonso-Curbelo D, Riveiro-Falkenbach E, Pérez-Guijarro E, et al. RAB7 control melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway. *Cancer Cell*. 2014;26:61-76.
22. García-Fernández M, Karras P, Checinska A, et al. Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of ATGS. *Autophagy*. 2016;12:1776-1790.